Incyte Corporation is looking to broaden its presence in the market for chronic graft-versus-host disease (cGVHD) therapies with a global deal to develop and commercialize Syndax Pharmaceuticals, Inc.’s monoclonal antibody for the drug, just days after Incyte’s flagship drug received US Food and Drug Administration approval for the same disease.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?